How targeted therapy disrupts the treatment paradigm for acquired TTP: The risks, benefits, and unknowns

Marshall A. Mazepa, Camila Masias, Shruti Chaturvedi

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor–platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

Original languageEnglish (US)
Pages (from-to)415-420
Number of pages6
JournalBlood
Volume134
Issue number5
DOIs
StatePublished - Aug 1 2019

Bibliographical note

Funding Information:
This work was supported by a Mentored Research Award from the Hemostasis and Thrombosis Research Society (S.C.). The funders had no role in preparation of the manuscript, or decision to publish.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Fingerprint Dive into the research topics of 'How targeted therapy disrupts the treatment paradigm for acquired TTP: The risks, benefits, and unknowns'. Together they form a unique fingerprint.

Cite this